Figure 2.

EGT does not increase priming and tumor-infiltration of CTLs. LLC-OVA-implanted WT B6 mice were treated as per Figure 1A. At day 18, tumor, spleen and draining lymph nodes (DLN: inguinal LN) were harvested. Then, population of OVA-tetramer positive cells (A) and total CD8⁺ CD3⁺ cells in tumor (B) were counted by flowcytometry. n = 4–5 mice per group. *P < 0.05. n.s., not significant.